infliximab + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing

Trial Timeline

May 1, 2005 → May 1, 2007

NCT ID

NCT00202865

About infliximab + Placebo

infliximab + Placebo is a phase 3 stage product being developed by Merck for Spondylitis, Ankylosing. The current trial status is completed. This product is registered under clinical trial identifier NCT00202865. Target conditions include Spondylitis, Ankylosing.

What happened to similar drugs?

20 of 20 similar drugs in Spondylitis, Ankylosing were approved

Approved (20) Terminated (4) Active (0)

✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved

✅GolimumabJohnson & JohnsonApproved

✅InfliximabMerckApproved

✅GolimumabMerckApproved

✅RemicadeMerckApproved

✅InfliximabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01313520	Phase 2	Completed	Mar 1, 2011	Mar 1, 2012	Arthritis, Rheumatoid
NCT00202865	Phase 3	Completed	May 1, 2005	May 1, 2007	Spondylitis, Ankylosing

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors

Product	Company	Stage	Hype Score
Infliximab	Celltrion	Phase 1	29
Infliximab	Celltrion	Phase 1	29
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
adalimumab	Eisai	Phase 3	40
Ixekizumab + Placebo + Adalimumab	Eli Lilly	Phase 3	32
Tramadol /acetaminophen + Diclofenac	Johnson & Johnson	Approved	35
Golimumab + Placebo	Johnson & Johnson	Phase 3	40
Golimumab	Johnson & Johnson	Approved	43
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 2/3	38
placebo for risankizumab + risankizumab	AbbVie	Phase 2	35
Upadacitinib + Placebo	AbbVie	Phase 2	35
Adalimumab	AbbVie	Pre-clinical	26
Infliximab	Merck	Approved	35
Infliximab + Placebo + Naproxen	Merck	Phase 3	40
Infliximab	Merck	Pre-clinical	26
Golimumab	Merck	Approved	43
Remicade	Merck	Approved	43
Remicade	Merck	Approved	43
Infliximab	Merck	Approved	43
Infliximab	Merck	Approved	35